Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair
暂无分享,去创建一个
[1] P. Poole,et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.
[2] P. Cayé-Thomasen,et al. Inhibition of phosphodiesterase 3, 4, and 5 induces endolymphatic hydrops in mouse inner ear, as evaluated with repeated 9.4T MRI , 2017, Acta oto-laryngologica.
[3] N. Plesnila,et al. Nitric oxide inhalation reduces brain damage, prevents mortality, and improves neurological outcome after subarachnoid hemorrhage by resolving early pial microvasospasms , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] D. Bennett,et al. Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells , 2016, Molecular Psychiatry.
[5] G. Pearlson,et al. Does Biology Transcend the Symptom-based Boundaries of Psychosis? , 2016, The Psychiatric clinics of North America.
[6] D. Pearse,et al. PDE4B as a microglia target to reduce neuroinflammation , 2016, Glia.
[7] J. O'Donnell,et al. Memory enhancement induced by PDE2 knockdown in an Alzheimer's disease model of mice , 2016 .
[8] P. Holtzheimer,et al. Deep Brain Stimulation for Depression: An Update , 2016, Current Behavioral Neuroscience Reports.
[9] R. Mirsky,et al. The repair Schwann cell and its function in regenerating nerves , 2016, The Journal of physiology.
[10] P. Fossa,et al. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies , 2016, Molecular Diversity.
[11] Yong Xu,et al. Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines , 2016, Journal of Neuroinflammation.
[12] D. Pearse,et al. Acute Putrescine Supplementation with Schwann Cell Implantation Improves Sensory and Serotonergic Axon Growth and Functional Recovery in Spinal Cord Injured Rats , 2015, Neural plasticity.
[13] J. Gensel,et al. Macrophage activation and its role in repair and pathology after spinal cord injury , 2015, Brain Research.
[14] F. Lezoualc’h,et al. Exchange protein directly activated by cAMP (EPAC) regulates neuronal polarization through Rap1B , 2016, The FASEB Journal.
[15] R. Caldwell,et al. Arginase: an old enzyme with new tricks. , 2015, Trends in pharmacological sciences.
[16] R. Franco,et al. Decreased levels of guanosine 3′, 5′‐monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease , 2015, Neuropathology and applied neurobiology.
[17] T. Palmer,et al. The future of EPAC-targeted therapies: agonism versus antagonism , 2015, Trends in pharmacological sciences.
[18] P. Gressens,et al. Nitric Oxide Pathway and Proliferation of Neural Progenitors in the Neonatal Rat , 2015, Developmental Neuroscience.
[19] M. Ghosh,et al. The Interplay between Cyclic AMP, MAPK, and NF-κB Pathways in Response to Proinflammatory Signals in Microglia , 2015, BioMed research international.
[20] S. Bhatt,et al. Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy , 2015, Psychopharmacology.
[21] H. Vinters,et al. Emerging concepts in Alzheimer's disease. , 2015, Annual review of pathology.
[22] P. Insel,et al. Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma , 2015, Proceedings of the National Academy of Sciences.
[23] O. Baud,et al. Impact of inhaled nitric oxide on white matter damage in growth-restricted neonatal rats , 2015, Pediatric Research.
[24] K. Ogita,et al. Beneficial effect of cilostazol‐mediated neuronal repair following trimethyltin‐induced neuronal loss in the dentate gyrus , 2015, Journal of neuroscience research.
[25] C. Atkins,et al. Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. , 2014, Current pharmaceutical design.
[26] P. Heckman,et al. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. , 2014, Current pharmaceutical design.
[27] J. Goldberg,et al. The role of soluble adenylyl cyclase in neurite outgrowth. , 2014, Biochimica et biophysica acta.
[28] Diana Boraschi,et al. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation , 2014, Front. Immunol..
[29] Srinath Krishnamurthy,et al. Active site coupling in PDE:PKA complexes promotes resetting of mammalian cAMP signaling. , 2014, Biophysical journal.
[30] M. Sitges,et al. The anti‐seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL‐1β and TNF‐α expression in rat hippocampus , 2014, Journal of neurochemistry.
[31] Jilly F. Evans,et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. , 2014, Cellular signalling.
[32] C. Mathis,et al. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition , 2014, Neurobiology of Aging.
[33] M. Fehlings,et al. Rho-ROCK inhibition in the treatment of spinal cord injury. , 2014, World neurosurgery.
[34] S. Tabrizi,et al. Targets for future clinical trials in Huntington's disease: What's in the pipeline? , 2014, Movement disorders : official journal of the Movement Disorder Society.
[35] E. Knott,et al. Cyclic AMP Signaling: A Molecular Determinant of Peripheral Nerve Regeneration , 2014, BioMed research international.
[36] C. Davies,et al. GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[37] Jane S. Paulsen,et al. Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.
[38] David Fox,et al. Structural basis for the design of selective phosphodiesterase 4B inhibitors. , 2014, Cellular signalling.
[39] O. Baud,et al. Sildenafil Mediates Blood-Flow Redistribution and Neuroprotection After Neonatal Hypoxia-Ischemia , 2014, Stroke.
[40] O. Baud,et al. Inhaled NO prevents hyperoxia-induced white matter damage in neonatal rats , 2014, Experimental Neurology.
[41] E. Fedele,et al. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D , 2014, Neuropharmacology.
[42] S. Endo,et al. Cilostazol improves hippocampus-dependent long-term memory in mice , 2014, Psychopharmacology.
[43] Ana Martínez,et al. Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. , 2014, ACS chemical neuroscience.
[44] Neelima Khairatkar-Joshi,et al. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors. , 2013, Bioorganic & medicinal chemistry letters.
[45] K. Bacallao,et al. Opposing Roles of pka and epac in the cAMP-Dependent Regulation of Schwann Cell Proliferation and Differentiation , 2013, PloS one.
[46] Zhong-Zhen Zhou,et al. Chlorbipram: a novel PDE4 inhibitor with improved safety as a potential antidepressant and cognitive enhancer. , 2013, European journal of pharmacology.
[47] D. Pearse,et al. Combining Neurotrophin-Transduced Schwann Cells and Rolipram to Promote Functional Recovery from Subacute Spinal Cord Injury , 2013, Cell transplantation.
[48] A. West,et al. Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. , 2013, Basal ganglia.
[49] D. Wallace,et al. Subcutaneous daidzein administration enhances recovery of skilled ladder rung walking performance following stroke in rats , 2013, Behavioural Brain Research.
[50] A. Ballester,et al. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.
[51] A. Geerts,et al. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines. , 2013, Molecular pharmaceutics.
[52] A. Giralt,et al. Regulation of Hippocampal cGMP Levels as a Candidate to Treat Cognitive Deficits in Huntington’s Disease , 2013, PloS one.
[53] I. Ferrer,et al. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease , 2013, Neurobiology of Aging.
[54] S. Morris,et al. Shaping the Murine Macrophage Phenotype: IL-4 and Cyclic AMP Synergistically Activate the Arginase I Promoter , 2013, The Journal of Immunology.
[55] K. Malpass. Multiple sclerosis: Regenerative therapies for MS—hope on the horizon , 2013, Nature Reviews Neurology.
[56] A. Giralt,et al. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model , 2013, Hippocampus.
[57] R. Morimoto,et al. Huntington's disease: underlying molecular mechanisms and emerging concepts. , 2013, Trends in biochemical sciences.
[58] Ana Martínez,et al. Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival , 2013, Cellular and Molecular Life Sciences.
[59] M. Filbin,et al. Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats , 2013, Behavioural Brain Research.
[60] M. Fehlings,et al. Emerging therapies for acute traumatic spinal cord injury , 2013, Canadian Medical Association Journal.
[61] E. Karran,et al. Corrigendum to “Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues” [Neuropharmacology 59 (2010) 367–374] , 2013, Neuropharmacology.
[62] M. Rusnak,et al. Traumatic brain injury: Giving voice to a silent epidemic , 2013, Nature Reviews Neurology.
[63] Xiao Lu,et al. Identification of Novel Phosphodiesterase-4D Inhibitors Prescreened by Molecular Dynamics-Augmented Modeling and Validated by Bioassay , 2013, J. Chem. Inf. Model..
[64] Y. Kang,et al. Age-dependent alterations in cAMP signaling contribute to synaptic plasticity deficits following traumatic brain injury , 2013, Neuroscience.
[65] N. Plesnila,et al. Inhaled Nitric Oxide Reduces Secondary Brain Damage after Traumatic Brain Injury in Mice , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[66] A. Sierksma,et al. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease , 2013, Neuropharmacology.
[67] J. Lanciego,et al. Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD , 2013, Neuropharmacology.
[68] P. New,et al. Global maps of non-traumatic spinal cord injury epidemiology: towards a living data repository , 2013, Spinal Cord.
[69] C. Atkins,et al. Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice , 2013, Neuroscience Letters.
[70] T. Hage,et al. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801 , 2013, Behavioural Brain Research.
[71] Paul Enright,et al. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts , 2012, BMJ Open.
[72] Alberto Lleó,et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease , 2012, Acta Neuropathologica.
[73] H. Bramlett,et al. Proinflammatory cytokine regulation of cyclic AMP‐phosphodiesterase 4 signaling in microglia in vitro and following CNS injury , 2012, Glia.
[74] R. Franco,et al. Phosphodiesterases as therapeutic targets for Alzheimer's disease. , 2012, ACS chemical neuroscience.
[75] D. Abo-Elmatty,et al. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats , 2012, Indian journal of pharmacology.
[76] P. Gressens,et al. Inhaled Nitric Oxide Reduces Brain Damage by Collateral Recruitment in a Neonatal Stroke Model , 2012, Stroke.
[77] Jeih-San Liow,et al. Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder , 2012, Biological Psychiatry.
[78] J. O'Donnell,et al. Evidence for Global Reduction in Brain Cyclic Adenosine Monophosphate Signaling in Depression , 2012, Biological Psychiatry.
[79] Samik Patel,et al. The Therapeutic Profile of Rolipram, PDE Target and Mechanism of Action as a Neuroprotectant following Spinal Cord Injury , 2012, PloS one.
[80] C. Stratakis. Cyclic AMP, Protein Kinase A, and Phosphodiesterases: Proceedings of an International Workshop , 2012, Hormone and Metabolic Research.
[81] F. Menniti,et al. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. , 2012, Journal of medicinal chemistry.
[82] N. Plesnila,et al. Nitric Oxide: Considerations for the Treatment of Ischemic Stroke , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[83] Eric R Kandel,et al. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB , 2012, Molecular Brain.
[84] S. Blumenthal. Earl Sutherland (1915-1975) and the Discovery of Cyclic AMP , 2012, Perspectives in biology and medicine.
[85] Jason J. Corneveaux,et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.
[86] Johannes Boltze,et al. Inhalation of Nitric Oxide Prevents Ischemic Brain Damage in Experimental Stroke by Selective Dilatation of Collateral Arterioles , 2012, Circulation research.
[87] D. Manahan‐Vaughan,et al. PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis , 2012, Translational Psychiatry.
[88] Jordan F Baye. Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. , 2012, P & T : a peer-reviewed journal for formulary management.
[89] E. Palazidou. The neurobiology of depression. , 2012, British medical bulletin.
[90] P. Sharma,et al. Neuroprotective effect of Vinpocetine against 3- NP Induced reduction of body weight and oxidative stress in Rats , 2012 .
[91] Pal Pacher,et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[92] C. C. Filgueiras,et al. Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder. , 2011, Drug and alcohol dependence.
[93] R. Franco,et al. Sildenafil restores cognitive function without affecting β‐amyloid burden in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.
[94] E. Fedele,et al. GEBR‐7b, a novel PDE4D selective inhibitor that improves memory in rodents at non‐emetic doses , 2011, British journal of pharmacology.
[95] Lynn A. Hyde,et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.
[96] A. Giralt,et al. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. , 2011, Human molecular genetics.
[97] D. Pearse,et al. A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury. , 2011, Journal of neurotrauma.
[98] M. Tresguerres,et al. Intracellular cAMP signaling by soluble adenylyl cyclase. , 2011, Kidney international.
[99] K. Taskén,et al. Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells. , 2011, Cellular signalling.
[100] K. Rabe. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease , 2011, British journal of pharmacology.
[101] G. Doronzo,et al. Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. , 2011, Atherosclerosis.
[102] J. Corbin,et al. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.
[103] M. Keshavan,et al. Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse , 2011, Schizophrenia Research.
[104] C. Pérez,et al. Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease , 2011, PloS one.
[105] Han-Ting Zhang,et al. Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats , 2011, Metabolic Brain Disease.
[106] Alan J. Thomas,et al. Neuropathological correlates of late-life depression in older people , 2011, British Journal of Psychiatry.
[107] P. Calabresi,et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.
[108] E. Mazzon,et al. PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury , 2011, PloS one.
[109] J. O'Donnell,et al. Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling , 2011, The Journal of Neuroscience.
[110] F. Colbatzky,et al. Inhibition of cyclooxygenase‐2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats , 2011, British journal of pharmacology.
[111] Ann Wu,et al. A preconditioning nerve lesion inhibits mechanical pain hypersensitivity following subsequent neuropathic injury , 2011, Molecular pain.
[112] T. Ferguson,et al. Extrinsic and intrinsic determinants of nerve regeneration , 2011, Journal of tissue engineering.
[113] M. Hiramatsu,et al. Cilostazol prevents amyloid β peptide25‐35‐induced memory impairment and oxidative stress in mice , 2010, British journal of pharmacology.
[114] R. Young,et al. Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. , 2010, Bioorganic & medicinal chemistry letters.
[115] G. Bernardi,et al. Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease , 2010, PloS one.
[116] G. Anand,et al. Phosphodiesterases Catalyze Hydrolysis of cAMP-bound to Regulatory Subunit of Protein Kinase A and Mediate Signal Termination* , 2010, Molecular & Cellular Proteomics.
[117] A. Nishi,et al. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. , 2010, Journal of pharmacological sciences.
[118] M. Houslay,et al. Cyclic AMP Controls mTOR through Regulation of the Dynamic Interaction between Rheb and Phosphodiesterase 4D , 2010, Molecular and Cellular Biology.
[119] M. Keshavan,et al. Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future , 2010, Schizophrenia Research.
[120] A. Hatzelmann,et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. , 2010, Pulmonary pharmacology & therapeutics.
[121] J. Jordán,et al. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF , 2010, Neurobiology of Disease.
[122] J. Strosznajder,et al. Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer's Disease , 2010, Molecular Neurobiology.
[123] F. Hofmann,et al. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes , 2010, Proceedings of the National Academy of Sciences.
[124] C. Lugnier,et al. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. , 2010, Current pharmaceutical design.
[125] M. Houslay. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.
[126] J. Bryson,et al. A Large-Scale Chemical Screen for Regulators of the Arginase 1 Promoter Identifies the Soy Isoflavone Daidzeinas a Clinically Approved Small Molecule That Can Promote Neuronal Protection or Regeneration via a cAMP-Independent Pathway , 2010, The Journal of Neuroscience.
[127] J. Bos,et al. Epac: defining a new mechanism for cAMP action. , 2010, Annual review of pharmacology and toxicology.
[128] Timothy Hagen,et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety , 2010, Nature Biotechnology.
[129] D. Schadendorf,et al. cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells , 2009, Cellular and Molecular Life Sciences.
[130] Tony Wyss-Coray,et al. Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little? , 2009, Neuron.
[131] Vivek Sharma,et al. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor. , 2009, European journal of pharmacology.
[132] M. Munder. Arginase: an emerging key player in the mammalian immune system , 2009, British journal of pharmacology.
[133] S. P. Bhatnagar,et al. A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. , 2009, Bioorganic & medicinal chemistry.
[134] J. Bryson,et al. Increased Synthesis of Spermidine as a Result of Upregulation of Arginase I Promotes Axonal Regeneration in Culture and In Vivo , 2009, The Journal of Neuroscience.
[135] Spiros Liras,et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. , 2009, Journal of medicinal chemistry.
[136] F. Menniti,et al. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. , 2009, Current opinion in drug discovery & development.
[137] A. Palmeri,et al. Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer's Disease Mouse Model , 2009, The Journal of Neuroscience.
[138] J. John Mann,et al. Antidepressants increase neural progenitor cells in the human hippocampus , 2009, Neuropsychopharmacology.
[139] Han-Ting Zhang. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. , 2009, Current pharmaceutical design.
[140] M. Wong,et al. Association of PDE11A global haplotype with major depression and antidepressant drug response , 2009, Neuropsychiatric disease and treatment.
[141] J. Bos,et al. Direct Spatial Control of Epac1 by Cyclic AMP , 2009, Molecular and Cellular Biology.
[142] G. Bernardi,et al. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington’s disease , 2009, The European journal of neuroscience.
[143] A. West,et al. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation , 2009, Journal of Pharmacology and Experimental Therapeutics.
[144] H. Daniel,et al. Epac mediates PACAP‐dependent long‐term depression in the hippocampus , 2009, The Journal of physiology.
[145] Takaichi Fukuda,et al. Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum , 2008, The Journal of Neuroscience.
[146] A. Dolga,et al. Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/Akt phosphorylation. , 2008, Cellular signalling.
[147] J. Zhu,et al. Epac signaling is required for hippocampus-dependent memory retrieval , 2008, Proceedings of the National Academy of Sciences.
[148] E. Neher,et al. Application of an Epac Activator Enhances Neurotransmitter Release at Excitatory Central Synapses , 2008, The Journal of Neuroscience.
[149] Andrew J. Murray,et al. Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration , 2008, Molecular and Cellular Neuroscience.
[150] A. Blokland,et al. Enhanced long‐term potentiation and impaired learning in phosphodiesterase 4D‐knockout (PDE4D−/−) mice , 2008, The European journal of neuroscience.
[151] D. Cabrol,et al. The PDE4 Inhibitor Rolipram Prevents NF-κB Binding Activity and Proinflammatory Cytokine Release in Human Chorionic Cells1 , 2008, The Journal of Immunology.
[152] M. Keshavan,et al. Neurobiology of the early course of schizophrenia , 2008, Expert review of neurotherapeutics.
[153] J. Strosznajder,et al. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging , 2008, Brain Research.
[154] D. Magnuson,et al. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury , 2008, Neuroscience Letters.
[155] Eric Klann,et al. Activation of exchange protein activated by cyclic-AMP enhances long-lasting synaptic potentiation in the hippocampus. , 2008, Learning & memory.
[156] J. O'Donnell,et al. Anxiogenic-Like Behavioral Phenotype of Mice Deficient in Phosphodiesterase 4B (PDE4B) , 2008, Neuropsychopharmacology.
[157] G. Bernardi,et al. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease , 2008, Neurobiology of Disease.
[158] R. D. Williams,et al. Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia , 2008, Journal of Pharmacology and Experimental Therapeutics.
[159] M. Beal,et al. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV , 2008, Experimental Neurology.
[160] J. Corbin,et al. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function , 2008, International Journal of Impotence Research.
[161] H. Yeh,et al. Synaptic Function for the Nogo-66 Receptor NgR1: Regulation of Dendritic Spine Morphology and Activity-Dependent Synaptic Strength , 2008, The Journal of Neuroscience.
[162] D. Aronoff,et al. Cyclic AMP: master regulator of innate immune cell function. , 2008, American journal of respiratory cell and molecular biology.
[163] M. Filbin,et al. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury , 2008, Experimental Neurology.
[164] S. Roscioni,et al. Epac: effectors and biological functions , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[165] H. Ke,et al. Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil , 2008, Molecular Pharmacology.
[166] J. Kleim,et al. A Novel Phosphodiesterase Type 4 Inhibitor, HT-0712, Enhances Rehabilitation-Dependent Motor Recovery and Cortical Reorganization After Focal Cortical Ischemia , 2007, Neurorehabilitation and neural repair.
[167] H. Bramlett,et al. Modulation of the cAMP signaling pathway after traumatic brain injury , 2007, Experimental Neurology.
[168] L. Fabbri,et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[169] J. Beavo,et al. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.
[170] L. Zhang,et al. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. , 2007, Biochemical pharmacology.
[171] G. Mengod,et al. Expression of the cGMP‐specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains , 2007, The European journal of neuroscience.
[172] Changping Yao,et al. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation , 2007, Neuroscience Letters.
[173] K. Jakobs,et al. Epac and the cardiovascular system. , 2007, Current opinion in pharmacology.
[174] V. Yong,et al. Characterization of the Early Neuroinflammation After Spinal Cord Injury in Mice , 2007, Journal of neuropathology and experimental neurology.
[175] Sydney Brenner,et al. Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. , 2007, Archives of neurology.
[176] J. Bockaert,et al. Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+-dependent K+ channels in cerebellar neurons , 2007, Proceedings of the National Academy of Sciences.
[177] G. Bernardi,et al. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity , 2007, Neurobiology of Disease.
[178] S. Karmakar,et al. Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate , 2006, Neuroscience.
[179] J. Bos,et al. Epac proteins: multi-purpose cAMP targets. , 2006, Trends in biochemical sciences.
[180] J. Mancini,et al. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. , 2006, Current medicinal chemistry.
[181] R. Cantor,et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.
[182] C. Steegborn,et al. Molecular details of cAMP generation in mammalian cells: a tale of two systems. , 2006, Journal of molecular biology.
[183] J. Beavo,et al. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.
[184] D. Rosskopf,et al. Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation* , 2006, Journal of Biological Chemistry.
[185] M. Giembycz. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. , 2006, British journal of clinical pharmacology.
[186] S. Døskeland,et al. Epac1 and cAMP-dependent Protein Kinase Holoenzyme Have Similar cAMP Affinity, but Their cAMP Domains Have Distinct Structural Features and Cyclic Nucleotide Recognition* , 2006, Journal of Biological Chemistry.
[187] T. Michaeli,et al. PDE7A1, a cAMP-specific Phosphodiesterase, Inhibits cAMP-dependent Protein Kinase by a Direct Interaction with C* , 2006, Journal of Biological Chemistry.
[188] R. B. Hart,et al. The Cytokine Interleukin-6 Is Sufficient But Not Necessary to Mimic the Peripheral Conditioning Lesion Effect on Axonal Growth , 2006, The Journal of Neuroscience.
[189] R. D. Williams,et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase , 2006, Neuroscience.
[190] K. Hsu,et al. Presynaptic Mechanism Underlying cAMP-Induced Synaptic Potentiation in Medial Prefrontal Cortex Pyramidal Neurons , 2006, Molecular Pharmacology.
[191] K. Sansam. Controversies in the management of traumatic spinal cord injury. , 2006, Clinical medicine.
[192] A. Blokland,et al. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action , 2006, Neurobiology of Learning and Memory.
[193] J. Schultz,et al. cAMP Is a Ligand for the Tandem GAF Domain of Human Phosphodiesterase 10 and cGMP for the Tandem GAF Domain of Phosphodiesterase 11* , 2006, Journal of Biological Chemistry.
[194] R. Biondi,et al. Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. , 2005, Molecular biology of the cell.
[195] Kam Y. J. Zhang,et al. Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.
[196] M. Houslay,et al. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. , 2005, Cellular signalling.
[197] R. H. Cote,et al. Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. , 2005, Investigative ophthalmology & visual science.
[198] E. Bateman,et al. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.
[199] Yin-ming Zeng,et al. Activation of ERK/CREB pathway in spinal cord contributes to chronic constrictive injury-induced neuropathic pain in rats , 2005, Acta Pharmacologica Sinica.
[200] K. Vranizan,et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[201] J. Langlois,et al. Traumatic Brain Injury Hospitalizations Among American Indians/Alaska Natives , 2005, The Journal of head trauma rehabilitation.
[202] H. Robertson,et al. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington′s disease transgenic mice prior to the onset of motor symptoms , 2004, Neuroscience.
[203] M. Pruniaux,et al. Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation1 , 2004, The Journal of Immunology.
[204] O. Vitolo,et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. , 2004, The Journal of clinical investigation.
[205] K. So,et al. Involvement of cAMP in neuronal survival and axonal regeneration , 2004, Anatomical science international.
[206] D. Ingram,et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats , 2004, Pharmacology Biochemistry and Behavior.
[207] Eric R. Kandel,et al. Activated CREB Is Sufficient to Overcome Inhibitors in Myelin and Promote Spinal Axon Regeneration In Vivo , 2004, Neuron.
[208] R. Ratan,et al. Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. , 2004, The Journal of nutrition.
[209] W. D. Dietrich,et al. Tumor Necrosis Factor &agr; Expression and Protein Levels after Fluid Percussion Injury in Rats: The Effect of Injury Severity and Brain Temperature , 2004, Neurosurgery.
[210] E. Vandenbussche,et al. Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation , 2004, Journal of Neurology.
[211] M. Fehlings,et al. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. , 2004, Journal of neurotrauma.
[212] Kam Y. J. Zhang,et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. , 2004, Molecular cell.
[213] M. Tuszynski,et al. Combinatorial Therapy with Neurotrophins and cAMP Promotes Axonal Regeneration beyond Sites of Spinal Cord Injury , 2004, The Journal of Neuroscience.
[214] M. Filbin,et al. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[215] M. Filbin,et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury , 2004, Nature Medicine.
[216] J. Kotera,et al. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP‐dependent protein kinase/cyclic AMP‐response element binding protein pathway in primary striatal neurons , 2004, Journal of neurochemistry.
[217] R. Duman,et al. Activation of cAMP Signaling Facilitates the Morphological Maturation of Newborn Neurons in Adult Hippocampus , 2004, The Journal of Neuroscience.
[218] M. Filbin,et al. A role for cAMP in regeneration of the adult mammalian CNS , 2004, Journal of anatomy.
[219] R. Bullock,et al. Clinical Trials in Traumatic Brain Injury: Lessons for the Future , 2004, Journal of neurosurgical anesthesiology.
[220] W. Mellado,et al. Neurotrophins Elevate cAMP to Reach a Threshold Required to Overcome Inhibition by MAG through Extracellular Signal-Regulated Kinase-Dependent Inhibition of Phosphodiesterase , 2003, The Journal of Neuroscience.
[221] R. Ricciardi,et al. Phosphorylation of Serine 337 of NF-κB p50 Is Critical for DNA Binding* , 2003, Journal of Biological Chemistry.
[222] A. Arnsten,et al. Dysregulation of Protein Kinase A Signaling in the Aged Prefrontal Cortex New Strategy for Treating Age-Related Cognitive Decline , 2003, Neuron.
[223] J. Eisenach,et al. Intrathecal injection of cAMP response element binding protein (CREB) antisense oligonucleotide attenuates tactile allodynia caused by partial sciatic nerve ligation , 2003, Brain Research.
[224] D. Umetsu,et al. PDE4D plays a critical role in the control of airway smooth muscle contraction , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[225] Pierre Voisin,et al. A proline-rich domain in the gamma subunit of phosphodiesterase 6 mediates interaction with SH3-containing proteins. , 2003, Molecular vision.
[226] S. Døskeland,et al. cAMP Analog Mapping of Epac1 and cAMP Kinase , 2003, Journal of Biological Chemistry.
[227] D. Hochbaum,et al. Activation of JNK by Epac Is Independent of Its Activity as a Rap Guanine Nucleotide Exchanger* , 2003, Journal of Biological Chemistry.
[228] J. Bos. Epac: a new cAMP target and new avenues in cAMP research , 2003, Nature Reviews Molecular Cell Biology.
[229] H. Kraemer,et al. Untreated depression and hippocampal volume loss. , 2003, The American journal of psychiatry.
[230] J. Palacios,et al. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer’s disease brains examined by in situ hybridization , 2003, Experimental Neurology.
[231] S. Døskeland,et al. cAMP effector mechanisms. Novel twists for an ‘old’ signaling system , 2003, FEBS letters.
[232] P. Soulard,et al. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. , 2003, International immunology.
[233] N. Sakurai,et al. Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. , 2003, Cellular signalling.
[234] G. Mengod,et al. cAMP-specific phosphodiesterases expression in Alzheimer's disease brains , 2003 .
[235] M. Houslay,et al. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. , 2003, The Biochemical journal.
[236] R. Segal,et al. p75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp , 2002, Nature.
[237] M. Conti,et al. Dimerization of the Type 4 cAMP-specific Phosphodiesterases Is Mediated by the Upstream Conserved Regions (UCRs)* , 2002, The Journal of Biological Chemistry.
[238] S. Jin,et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.
[239] J. O'Donnell,et al. Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme , 2002, Neuropsychopharmacology.
[240] C. Webster,et al. cAMP inhibits bile acid-induced apoptosis by blocking caspase activation and cytochrome c release. , 2002, American journal of physiology. Gastrointestinal and liver physiology.
[241] J. Beavo,et al. Cyclic nucleotide research — still expanding after half a century , 2002, Nature Reviews Molecular Cell Biology.
[242] P. Thibault,et al. Oligodendrocyte‐myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth , 2002, Journal of neurochemistry.
[243] W. Mellado,et al. Arginase I and Polyamines Act Downstream from Cyclic AMP in Overcoming Inhibition of Axonal Growth MAG and Myelin In Vitro , 2002, Neuron.
[244] W. D. Dietrich,et al. Interleukin-1β Messenger Ribonucleic Acid and Protein Levels after Fluid-Percussion Brain Injury in Rats: Importance of Injury Severity and Brain Temperature. , 2002, Neurosurgery.
[245] Ian McPhee,et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A‐mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1) , 2002, British journal of pharmacology.
[246] R. Sunahara,et al. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. , 2002, Molecular interventions.
[247] M. Morganti-Kossmann,et al. Inflammatory response in acute traumatic brain injury: a double-edged sword , 2002, Current opinion in critical care.
[248] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[249] S. Takeo,et al. Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism‐induced defects in memory function and cerebral cyclic AMP signal transduction system in rats , 2002, British journal of pharmacology.
[250] K. Jin,et al. MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad , 2002, Journal of neurochemistry.
[251] M. Billah,et al. Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. , 2001, Gene.
[252] Marc Montminy,et al. Transcriptional regulation by the phosphorylation-dependent factor CREB , 2001, Nature Reviews Molecular Cell Biology.
[253] L. Levin,et al. Bicarbonate-regulated soluble adenylyl cyclase. , 2001, JOP : Journal of the pancreas.
[254] S. R. Datta,et al. Transcription-dependent and -independent control of neuronal survival by the PI3K–Akt signaling pathway , 2001, Current Opinion in Neurobiology.
[255] A. Fournier,et al. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration , 2001, Nature.
[256] John Calvin Reed,et al. MEK/ERK signaling pathway regulates the expression of Bcl‐2, Bcl‐XL, and Mcl‐1 and promotes survival of human pancreatic cancer cells , 2000, Journal of cellular biochemistry.
[257] G. Baillie,et al. Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterases , 2000, British journal of pharmacology.
[258] Y. Zhao,et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. , 2000, Science.
[259] G. Baillie,et al. ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases , 2000, The Journal of Biological Chemistry.
[260] R. Hicks,et al. Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system , 2000, Journal of Neuroimmunology.
[261] B. Boulanger,et al. Beta adrenoceptor regulation of macrophage arginase activity. , 2000, Surgery.
[262] R. Zucker,et al. Enhancement of synaptic transmission by cyclic AMP modulation of presynaptic Ih channels , 2000, Nature Neuroscience.
[263] Fumio Nakamura,et al. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein , 2000, Nature.
[264] Martin E. Schwab,et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1 , 2000, Nature.
[265] R. Prinjha,et al. Neurobiology: Inhibitor of neurite outgrowth in humans , 2000, Nature.
[266] S. Kish,et al. Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims. , 1999, Journal of affective disorders.
[267] S. R. Datta,et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.
[268] N. Leclerc,et al. Inactivation of Rho Signaling Pathway Promotes CNS Axon Regeneration , 1999, The Journal of Neuroscience.
[269] F. Hayashi,et al. Suppression of GTP/T alpha-dependent activation of cGMP phosphodiesterase by ADP-ribosylation by its gamma subunit in amphibian rod photoreceptor membranes. , 1999, Biochemistry.
[270] G. Baillie,et al. The MAP kinase ERK2 inhibits the cyclic AMP‐specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579 , 1999, The EMBO journal.
[271] F. D. Tattersall,et al. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret , 1999, Neuropharmacology.
[272] E. Kandel,et al. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[273] A. Wittinghofer,et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP , 1998, Nature.
[274] G. MacQueen,et al. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression , 1998, The Lancet.
[275] M. Hanson,et al. Depolarization and cAMP Elevation Rapidly Recruit TrkB to the Plasma Membrane of CNS Neurons , 1998, Neuron.
[276] P. Heinrich,et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.
[277] L. Lim,et al. cAMP-induced Morphological Changes Are Counteracted by the Activated RhoA Small GTPase and the Rho Kinase ROKα* , 1998, The Journal of Biological Chemistry.
[278] M. Houslay,et al. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. , 1998, The Biochemical journal.
[279] B. Bregman,et al. Transplants and Neurotrophic Factors Prevent Atrophy of Mature CNS Neurons after Spinal Cord Injury , 1998, Experimental Neurology.
[280] K. Sluka. Activation of the cAMP transduction cascade contributes to the mechanical hyperalgesia and allodynia induced by intradermal injection of capsaicin , 1997, British journal of pharmacology.
[281] A. Sawa,et al. Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. , 1997, Japanese journal of pharmacology.
[282] M. Ohashi,et al. Residues within the polycationic region of cGMP phosphodiesterase gamma subunit crucial for the interaction with transducin alpha subunit. Identification by endogenous ADP-ribosylation and site-directed mutagenesis. , 1997, The Journal of biological chemistry.
[283] N. Artemyev,et al. The γ Subunit of Rod cGMP-Phosphodiesterase Blocks the Enzyme Catalytic Site* , 1997, The Journal of Biological Chemistry.
[284] M. Teixeira,et al. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? , 1997, Trends in pharmacological sciences.
[285] P. Peterson,et al. CYTOKINE-MEDIATED NEURONAL APOPTOSIS , 1997, Neurochemistry International.
[286] T. Yamamoto,et al. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. , 1997, European journal of pharmacology.
[287] T. Gordon,et al. The cellular and molecular basis of peripheral nerve regeneration , 1997, Molecular Neurobiology.
[288] A. Rajput,et al. Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. , 1996, Life Science.
[289] T. Robbins,et al. Executive and mnemonic functions in early Huntington's disease. , 1996, Brain : a journal of neurology.
[290] D. Wallach,et al. Inhibition of Tumor Necrosis Factor Alpha (TNFα) Activity in Rat Brain is Associated with Cerebroprotection after Closed Head Injury , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[291] J. Csernansky,et al. Hippocampal atrophy in recurrent major depression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[292] P. Young,et al. Experimental brain injury induces differential expression of tumor necrosis factor-alpha mRNA in the CNS. , 1996, Brain research. Molecular brain research.
[293] R. Stancou,et al. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. , 1996, The EMBO journal.
[294] P. Hulley,et al. Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra Neurons In Vivo , 1995, The European journal of neuroscience.
[295] R J Heaslip,et al. Emetic, central nervous system, and pulmonary activities of rolipram in the dog. , 1995, European journal of pharmacology.
[296] M. Conti,et al. Phosphorylation and Activation of a cAMP-specific Phosphodiesterase by the cAMP-dependent Protein Kinase , 1995, The Journal of Biological Chemistry.
[297] E. Degerman,et al. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. , 1995, Archives of biochemistry and biophysics.
[298] K. Hashimoto,et al. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. , 1995, European journal of pharmacology.
[299] E. Siemers,et al. Cognitive scores in carriers of huntington's disease gene compared to noncarriers , 1995, Annals of neurology.
[300] D. Ferrari,et al. Activation of microglial cells by β-amyloid protein and interferon-γ , 1995, Nature.
[301] M. Greenberg,et al. Serine 133-Phosphorylated CREB Induces Transcription via a Cooperative Mechanism That May Confer Specificity to Neurotrophin Signals , 1995, Molecular and Cellular Neuroscience.
[302] D. Yarnall,et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.
[303] M. Modolell,et al. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. , 1995, Biochemical and biophysical research communications.
[304] L. Mckerracher,et al. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth , 1994, Neuron.
[305] M. Filbin,et al. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration , 1994, Neuron.
[306] W. K. Sonnenburg,et al. Phosphorylation of the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase at serine 120 reduces its affinity for calmodulin. , 1994, Biochemistry.
[307] G. B. Wisely,et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. , 1994, Journal of immunology.
[308] JW Polli,et al. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[309] J. Marcusson,et al. Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims , 1994, Brain Research.
[310] C. Saper,et al. Distribution and characterization of tumor necrosis factor‐α‐like immunoreactivity in the murine central nervous system , 1993 .
[311] M. Wigler,et al. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs , 1993, Molecular and cellular biology.
[312] P. Barie,et al. Human astrocyte production of tumour necrosis factor-α, interleukin-1β, and interleukin-6 following exposure to lipopolysaccharide endotoxin , 1993 .
[313] J. Bénavidès,et al. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand , 1993, Journal of Neuroimmunology.
[314] M. Conti,et al. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain. , 1992, The Journal of biological chemistry.
[315] J. Corbin,et al. A phenylalanine in peptide substrates provides for selectivity between cGMP- and cAMP-dependent protein kinases. , 1992, The Journal of biological chemistry.
[316] L. Gaal,et al. Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo. , 1992, European journal of pharmacology.
[317] J. Silver,et al. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[318] C H Tator,et al. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. , 1991, Journal of neurosurgery.
[319] T. Soderling,et al. Regulation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase by the autophosphorylated form of Ca2+/calmodulin-dependent protein kinase II. , 1989, The Journal of biological chemistry.
[320] M. Montminy,et al. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene , 1987, Nature.
[321] V. Denoble. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats , 1987, Pharmacology Biochemistry and Behavior.
[322] R. Butcher,et al. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. , 1962, The Journal of biological chemistry.
[323] D. Ingram,et al. Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. , 2014, NeuroRehabilitation.
[324] M. Gurney,et al. Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease , 2014, Neurotherapeutics.
[325] M. A. Moro,et al. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. , 2012, European journal of medicinal chemistry.
[326] K. Rabe,et al. The Efficacy and Safety of Cilomilast in COPD , 2012, Drugs.
[327] M. Houslay,et al. Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. , 2011, Handbook of experimental pharmacology.
[328] J. O'Donnell,et al. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. , 2011, Handbook of experimental pharmacology.
[329] T. Kleppisch. Phosphodiesterases in the central nervous system. , 2009, Handbook of experimental pharmacology.
[330] S. Strittmatter,et al. Axon regeneration in the peripheral and central nervous systems. , 2009, Results and problems in cell differentiation.
[331] J. Siuciak. The Role of Phosphodiesterases in Schizophrenia , 2008, CNS drugs.
[332] Susan S. Taylor,et al. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. , 2008, Biochimica et biophysica acta.
[333] M. Tymianski,et al. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death , 2007, Molecular Neurobiology.
[334] J. Gies,et al. Heptahelical and other G-protein-coupled receptors (GPCRs) signaling. , 2006, Current medicinal chemistry.
[335] R. Cote. Cyclic guanosine 5'-monophosphate binding to regulatory GAF domains of photoreceptor phosphodiesterase. , 2005, Methods in molecular biology.
[336] K. Kinoshita,et al. The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma. , 2004, Acta neurochirurgica. Supplement.
[337] G. Smith,et al. Peripheral nerve grafts lacking viable Schwann cells fail to support central nervous system axonal regeneration , 2004, Experimental Brain Research.
[338] S. Gordon. Alternative activation of macrophages , 2003, Nature Reviews Immunology.
[339] Yogesh K. Dwivedi,et al. [(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. , 2002, The American journal of psychiatry.
[340] E. Huang,et al. Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.
[341] J. Hanoune,et al. Regulation and role of adenylyl cyclase isoforms. , 2001, Annual review of pharmacology and toxicology.
[342] E. Degerman,et al. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.
[343] L. Staib,et al. Hippocampal volume reduction in major depression. , 2000, The American journal of psychiatry.
[344] M. Filbin,et al. Prior Exposure to Neurotrophins Blocks Inhibition of Axonal Regeneration by MAG and Myelin via a cAMP-Dependent Mechanism , 1999, Neuron.
[345] J. Habener,et al. Cyclic AMP signaling and gene regulation. , 1998, Annual review of nutrition.
[346] M. Houslay,et al. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.
[347] S R Sprang,et al. G protein mechanisms: insights from structural analysis. , 1997, Annual review of biochemistry.
[348] Douglas H. Smith,et al. Temporal and spatial characterization of neuronal injury following lateral fluid-percussion brain injury in the rat , 1996, Acta Neuropathologica.
[349] Y. Katayama,et al. Excitatory amino acid release from contused brain tissue into surrounding brain areas. , 1994, Acta neurochirurgica. Supplementum.
[350] I. Hindmarch,et al. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. , 1991, International clinical psychopharmacology.